Down-regulation of interleukin-2 and interferon-γ and maintenance of interleukin-4 and interleukin-10 production after administration of an anti- CD3 monoclonal antibody in mice

Transplantation

Volumn 68, Issue 5, 1999, Pages 677-684

  Wissing, K Martin ^a   Desalle, Fabrice ^b   Abramowicz, Daniel ^a   Willems, Fabienne ^b   Leo, Oberdan ^b   Goldman, Michel ^b   Alegre, Maria Luisa ^c  

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MONOCLONAL ANTIBODY; OKT 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; FEMALE; GRAFT SURVIVAL; INTERFERON INDUCTION; INTERFERON PRODUCTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN ALLOGRAFT; SPLEEN CELL; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD3; FEMALE; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; LYMPHOCYTE COUNT; MALE; MICE; MICE, INBRED STRAINS; SKIN TRANSPLANTATION; SPLEEN; T-LYMPHOCYTES;

EID: 0033567981     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199909150-00014     Document Type: Article

References (53)

1. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337.
2. Opelz G. Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Transplantation 1995; 60: 1220.
3. Abramowicz D, Norman DJ, Vereerstraeten P, et al. OKT3 prophylaxis in renal grafts with prolonged ischemia times: association with improvement in long-term survival. Kidney Int 1996; 49: 768.
4. Chatenoud L, Baudrihaye MF, Kreis H, Goldstein G, Schindler J, Bach JF. Human in vivo antigenic modulation induced by anti-T cell OKT3 monoclonal antibody. Eur J Immunol 1982; 12: 979.
5. Buysmann S, Bemelman FJ, Schellekens PT, van Kooyk Y, Figdor CG, ten Berge IJ. Activation and increased expression of adhesion molecules on peripheral blood lymphocytes is a mechanism for the immediate lymphocytopenia after administration of OKT3. Blood 1996; 87: 404.
6. Hirsch R, Eckhaus M, Auchincloss H, Sachs DH, Bluestone JA. Effect of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses. J Immunol 1988; 140: 3766.
7. Mackie JD, Pankewycz OG, Bastos MG, Kelley VE, Strom TB. Dose-related mechanisms of immunosuppression mediated by murine anti-CD3 monoclonal antibody in pancreatic islet cell transplantation and delayed-type hypersensitivity. Transplantation 1990; 49: 1150.
8. Willems F, Andris F, Xu D, et al. The induction of human T cell unresponsiveness by soluble anti-CD3 mAb requires T cell activation. Int Immunol 1995; 7: 1593.
9. Woodle ES, Hussein S, Bluestone JA. In vivo administration of anti-murine CD3 monoclonal antibody induces selective, longterm anergy in CD8+ T cells. Transplantation 1996; 61: 798.
10. Williams ME, Shea CM, Lichtman AH, Abbas AK. Antigen receptor-mediated anergy in resting T lymphocytes and T cell clones. Correlation with lymphokine secretion patterns. J Immunol 1992; 149: 1921.
11. Gajewski TF, Lancki DW, Stack R, Fitch FW. "Anergy" of TH0 helper T lymphocytes induces downregulation of TH1 characteristics and a transition to a TH2-like phenotype. J Exp Med 1994; 179: 481.
12. Ben Amor A, Leite De Moraes MC, Lepault F, et al. In vitro T cell unresponsiveness following low-dose injection of anti-CD3 MoAb. Clin Exp Immunol 1996; 103: 491.
13. Alegre ML, Tso JY, Sattar HA, et al. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J Immunol 1995; 155: 1544.
14. Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci USA 1987; 84: 1374.
15. Abrams JS, Roncarlo MG, Yssel H, Andersson U, Gleich GJ, Silver JE. Strategies of anti-cytokine monoclonal antibody development: Immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev 1992; 127: 5.
16. Ohara J, Paul WE. Production of a monoclonal antibody to and characterization of B-cell stimulatory factor-1. Nature 1985; 315: 333.
17. Mosmann TR, Fong TAT. Specific assays for cytokine production by T cells. J Immunol Methods 1989; 116: 151.
18. Wissing M, Alegre ML, Abramowicz D, et al. Emergence of Th2-like cells after anti-CD3 monoclonal antibody administration in mice. Transplant Proc 1995; 27: 378.
19. Vossen AC, Tibbe GJ, Kroos MJ, van de Winkel JG, Benner R, Savelkoul HF. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects. Eur J Immunol 1995; 25: 1492.
20. Andris F, Van Mechelen M, De Mattia F, Baus E, Urbain J, Leo O. Induction of T cell unresponsiveness by anti-CD3 antibodies occurs independently of co-stimulatory functions. Eur J Immunol 1996; 26: 1187.
21. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787.
22. Muraille E, De Smedt T, Andris F, et al. Staphylococcal enterotoxin B induces an early and transient state of immunosuppression characterized by V beta-unrestricted T cell unresponsiveness and defective antigen-presenting cell functions. J Immunol 1997; 158: 2638.
23. Florquin S, Amraoui Z, Goldman M. Persistent production of Th-2 type cytokines and polyclonal B cell activation after chronic administration of staphylococcal enterotoxin B in mice. J Autoimmun 1996; 9: 609.
24. Florquin S, Amraoui Z, Goldman M. T cells made deficient in interleukin-2 production by exposure to staphylococcal enterotoxin B in vivo are primed for interferon-γ and interleukin-10 secretion. Eur J Immunol 1995; 25; 1148.
25. Baschieri S, Lees RK, Lussow AR, MacDonald HR. Clonal anergy to staphylococcal enterotoxin B in vivo: selective effects on T cell subsets and lymphokines. Eur J Immunol 1993; 23: 2661.
26. Ramsdell F, Seaman MS, Miller RE, Picha KS, Kennedy MK, Lynch DH. Differential ability of Th1 and Th2 T cells to express Fas ligand and to undergo activation-induced cell death. Int Immunol 1994; 6: 1545.
27. Zhang L, Miller RG, Zhang J Characterization of apoptosisresistant antigen-specific T cells in vivo. J Exp Med 1996; 183: 2065.
28. Zhang X, Brunner T, Carter L, et al. Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med 1997; 185: 1837.
29. Chai JG, Lechler RI. Immobilized anti-CD3 mAb induces anergy in murine naive and memory CD4+ T cells in vitro. Int Immunol 1997; 9: 935.
30. Flamand V, Abramowicz D, Goldman M, et al. Anti-CD3 antibodies induce T cells from unprimed animals to secrete IL-4 both in vitro and in vivo. J Immunol 1990; 144: 2875.
31. Durez P, Abramowicz D, Gerard C, et al. In vivo induction of interleukin 10 by anti-CD3 monoclonal antibody or bacterial lipopolysaccharide: differential modulation by cyclosporin A. J Exp Med 1993; 177: 551.
32. Takeuchi T, Lowry RP, Konieczny B. Heart allografts in murine systems. The differential activation of Th2-like effector cells in peripheral tolerance. Transplantation 1992; 53: 1281.
33. Siegling A, Lehmann M, Riedel H, et al. A non-depleting anti-rat CD4 mAb that suppresses T helper 1-like but not T helper 2-like intragraft lymphokine secretion induces long-term survival of renal allografts. Transplantation 1994; 57: 464.
34. Donckier V, Wissing M, Bruyns C, et al. Critical role of interleukin 4 in the induction of neonatal transplantation tolerance. Transplantation 1995; 59: 1571.
35. Davies JD, Martin G, Phillips J, Marshall SA, Cobbold SP, Waldmann H. T cell regulation in adult transplantation tolerance. J Immunol 1996; 157: 529.
36. Punch JD, Tono T, Qin L, Bishop DK, Bromberg JS. Tolerance induction by anti-CD2 plus anti-CD3 monoclonal antibodies: Evidence for an IL-4 requirement. J Immunol 1998; 161: 1156.
37. Scully R, Cobbold SP, Mellor AL, Wissing M, Arnold B, Waldmann H. A role for Th2 cytokines in the suppression of CD8 T cell-mediated graft rejection. Eur J Immunol 1997; 27: 1663.
38. VanBuskirk AM, Wakely ME, Orosz CG. Transfusion of polarized TH2-like cell populations into SCID mouse cardiac allograft recipients results in acute allograft rejection. Transplantation 1996; 62: 229.
39. Piccotti JR, Chan SY, Goodman RE, Magram J, Eichwald EJ, Bishop DK. IL-12 antagonism induces T helper 2 responses, yet exacerbates cardiac allograft rejection. Evidence against a dominant protective role for T helper 2 cytokines in alloimmunity. J Immunol 1996; 157: 1951.
40. Fanslow WC, Clifford KN, Park LS, et al. Regulation of alloreactivity in vivo by IL-4 and the soluble IL-4 receptor. J Immunol 1991; 147: 535.
41. Qian S, Wei L, Li Y, et al. Systemic administration of cellular interleukin-10 can exacerbate cardiac allograft rejection in mice. Transplantation 1996; 62: 1709.
42. Zheng XX, Steele AW, Nickerson PW, Steurer W, Steiger J, Strom TB. Administration of noncytolytic IL-10Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J Immunol 1995; 154: 5590.
43. Blazar Br, Taylor PA, Smith S, Vallera DA. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood 1995; 85: 842.
44. Wissing KM, Morelon E, Legendre C, et al. A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy. Transplantation 1997; 64: 999.
45. Xu GP, Sharma VK, Li B, et al. Intragraft expression of IL-10 messenger RNA: a novel correlate of renal allograft rejection. Kidney Int 1995; 48: 1504.
46. 4 integrm/ VCAM-1 adhesion pathways. J Immunol 1998; 160: 5637.
47. Widmer MB, Grabstein KH. Regulation of cytolytic T lymphocyte generation by B-cell stimulating factor. Nature 1987; 326: 795.
48. Chen WF, Zlotnik A. IL-10: a novel cytotoxic T cell differentiation factor. J Immunol 1991; 147: 528.
49. Itoh K, Hirohata S. The role of IL-10 in human B cell activation, proliferation, and differentiation. J Immunol 1995; 154: 4341.
50. Essner R, Rhoades K, McBride WH, Morton DL, Economou JS. IL-4 down-regulates IL-1 and TNF gene expression in human monocytes. J Immunol 1989; 142: 3857.
51. Fiorentino DF, Zlotnik A, Vieira P, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146: 3444.
52. De Smedt T, Van Mechelen M, De Becker G, Urbain J, Leo O, Moser M. Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol 1997; 27: 1229.
53. Delvaux A, Donckier V, Bruyns C, et al. Effects of systemic administration of rIL-10 in an in vivo model of alloreactivity. Transplantation 1994; 58: 972.